Metastatic gastric cancer – focus on targeted therapies

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• SuganoKGastric cancer: pathogenesis, screening and treatmentGastrointest Endosc Clin N Am200818351352218674700
   PubMedGoogle Scholar
• WagnerADGrotheWHaertingJKleberGGrotheyAFleigWEChemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate dataJ Clin Oncol200624182903290916782930
   PubMed Web of Science ®Google Scholar
• CunninghamDStarlingNRaoSCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med20083581364618172173
   PubMed Web of Science ®Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• PowerDGKelsenDPShahMAAdvanced gastric cancer – slow but steady progressCancer Treat Rev201036538439220176443
   PubMed Web of Science ®Google Scholar
• OkinesAFReynoldsARCunninghamDTargeting angiogenesis in esophagogastric adenocarcinomaOncologist201116684485821632459
   PubMed Web of Science ®Google Scholar
• MaedaKChungYSOgawaYPrognostic value of vascular endothelial growth factor expression in gastric carcinomaCancer19967758588638608475
   PubMed Web of Science ®Google Scholar
• YoshikawaTTsuburayaAKobayashiOPlasma concentration of VEGF and bFGF in patients with gastric carcinomaCancer Lett20001531–271210779624
   PubMed Web of Science ®Google Scholar
• ShahMARamanathanRKIlsonDHMulticenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol200624335201520617114652
   PubMed Web of Science ®Google Scholar
• ShahMAJhawerMIlsonDHPhase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinomaJ Clin Oncol201129786887421189380
   PubMed Web of Science ®Google Scholar
• EnzingerPRyanDReganEPhase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancerJ Clin Oncol200826Suppl 15S4552
   Web of Science ®Google Scholar
• El-RayesBFZalupskiMBekai-SaabTA phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancersAnn Oncol201021101999200420332133
   PubMed Web of Science ®Google Scholar
• CohenuramMKLacyJFOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal, gastroesophageal (GE) and gastric cancer (G) adenocarcinoma: a single institution’s initial clinical experienceProceedings of GI ASCO200874
   Google Scholar
• OhtsuAShahMAVan CutsemEBevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyJ Clin Oncol20201129303968397621844504
   PubMed Web of Science ®Google Scholar
• ShahMKangYOhtsuATumor and blood plasma biomarker analyses in the AVAGAST phase III randomized study of first-line bevacizumab + capecitabine/cisplatin in patients with advanced gastric cancerAnn Oncol201021Suppl 8S176
   Google Scholar
• SpratlinJLCohenRBEadensMPhase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2J Clin Oncol201028578078720048182
   PubMed Web of Science ®Google Scholar
• KimCLeeJLChoiYHPhase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancerInvest New Drugs201230130631520839031
   PubMed Web of Science ®Google Scholar
• SunWPowellMO’DwyerPJPhase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203J Clin Oncol201028182947295120458043
   PubMed Web of Science ®Google Scholar
• BangYJKangYKKangWKPhase II study of sunitinib as second-line treatment for advanced gastric cancerInvest New Drugs2011296L14491458
   PubMed Web of Science ®Google Scholar
• MoehlerMMuellerAHartmannJTAn open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancerEur J Cancer201147101511152021561763
   PubMed Web of Science ®Google Scholar
• SatohTYamadaYMuroKPhase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancerCancer Chemother Pharmacol201269243944621853311
   PubMed Web of Science ®Google Scholar
• MaedaKChungYSTakatsukaSTumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinomaBr J Cancer19957223193237543771
   PubMed Web of Science ®Google Scholar
• JüttnerSWissmannCJönsTVascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinomaJ Clin Oncol200624222824016344322
   PubMed Web of Science ®Google Scholar
• DingSLiCLinSDistinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinomaOncol Rep200717236937517203176
   PubMed Web of Science ®Google Scholar
• LurjeGLeersJMPohlAGenetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagusAnn Surg2010251585786420101173
   PubMed Web of Science ®Google Scholar
• AhnJBRhaSYShinSJCirculating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patientsCancer Lett2010288112413219619937
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206J Clin Oncol201028132137214320368558
   PubMed Web of Science ®Google Scholar
• ShojaeiFFerraraNRole of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapiesDrug Resist Updat200811621923018948057
   PubMed Web of Science ®Google Scholar
• AzamFMehtaSHarrisALMechanisms of resistance to antiangiogenesis therapyEur J Cancer20104681323133220236818
   PubMed Web of Science ®Google Scholar
• EikesdalHPKalluriRDrug resistance associated with antiangiogenesis therapySemin Cancer Biol200919531031719524042
   PubMed Web of Science ®Google Scholar
• MaJWaxmanDJCombination of antiangiogenesis with chemotherapy for more effective cancer treatmentMol Cancer Ther20087123670368419074844
   PubMed Web of Science ®Google Scholar
• MendelsohnJTargeting the epidermal growth factor receptor for cancer therapyJ Clin Oncol200220Suppl 18S1S13
   PubMed Web of Science ®Google Scholar
• OkinesACunninghamDChauITargeting the human EGFR family in esophagogastric cancerNat Rev Clin Oncol20118849250321468131
   PubMed Web of Science ®Google Scholar
• CappettaALonardiSPastorelliDBergamoFLombardiGZagonelVAdvanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapiesCrit Rev Oncol Hematol2012811384821256046
   PubMed Web of Science ®Google Scholar
• EnzingerPCBurtnessBHollisDCALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancerJ Clin Oncol201028Suppl 15a4006
   Google Scholar
• ChanJABlaszkowskyLSEnzingerPCA multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaAnn Oncol20112261367137321217058
   PubMed Web of Science ®Google Scholar
• GoldPJGoldmanBIqbalSCetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)J Thorac Oncol2010591472147620631636
   PubMed Web of Science ®Google Scholar
• TebbuttNCSourjinaTStricklandAHATTAX2: docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer-final results of a multicentre phase II trial by the AGITGProceedings of the GI ASCO2008a87
   Google Scholar
• SteinAAl-BatranSEArnoldDPeinertSSiewczynskiRSchmollHJCetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancerProceedings of the GI ASCO2007a47
   Google Scholar
• RaoSStarlingNCunninghamDMatuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II studyAnn Oncol201021112213221920497967
   PubMed Web of Science ®Google Scholar
• KimYHSasakiYLeeKHRandomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary resultsJ Clin Oncol201129Suppl 4a87
   Web of Science ®Google Scholar
• DragovichTMcCoySFenoglio-PreiserCMPhase II trial of erlotinib in gastrooesophageal junction and gastric adenocarcinomas: SWOG 0127J Clin Oncol2006249304922492717050876
   PubMed Web of Science ®Google Scholar
• RojoFTaberneroJAlbanellJPharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinomaJ Clin Oncol200624264309431616963731
   PubMed Web of Science ®Google Scholar
• RodriguezCPAdelsteinDJRiceTWA phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancerJ Thorac Oncol20105222923520009775
   PubMed Web of Science ®Google Scholar
• FornaroLLucchesiMCaparelloCAnti-HER agents in gastric cancer: from bench to bedsideNat Rev Gastroenterol Hepatol20118736938321647199
   PubMed Web of Science ®Google Scholar
• Meza-JuncoJAuHJSawyerMBCritical appraisal of trastuzumab in treatment of advanced stomach cancerCancer Manag Res20113576421556317
   PubMedGoogle Scholar
• BangYChungHXuJPathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trialJ Clin Oncol200927Suppl 15Sa4556
   Google Scholar
• GongSJJinCJRhaSYChungHCGrowth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell linesCancer Lett2004214221522415363548
   PubMed Web of Science ®Google Scholar
• Cortés-FunesHRiveraFAlésIPhase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplificationJ Clin Oncol200725Suppl 18a4613
   Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• IqbalSGoldmanBLenzHJFenoglio-PreiserCMBlankeCDS0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancerJ Clin Oncol200725Suppl 18a4621
   Web of Science ®Google Scholar
• HechtJUrbaSGKoehlerMLapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analysesThe Proceedings of GI ASCO2008a43
   Google Scholar
• LenzHZhangWKemnerAMLapatinib 1 capecitabine in advanced gastric cancer: An open-label phase II study of non ERBB2-targeted diseaseAnn Oncol201021Suppl 8S817
   Google Scholar
• RothAMoehlerMHMauerMLapatinib in combination with ECF/X in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): a phase II randomized placebo controlled trial (EORTC 40071)J Clin Oncol201028Suppl 15a205
   Web of Science ®Google Scholar
• SatohTBangYWangJInterim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancerJ Clin Oncol201028Suppl 15a4057
   Web of Science ®Google Scholar
• ClinicalTrials.govLOGiC – Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Available at: http://clinicaltrials.gov/ct2/show/NCT00680901?term=LOGiC&rank=8
   Google Scholar
• Di FioreFSesboüéRMichelPSabourinJCFrebourgTMolecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancerBr J Cancer2010103121765177221139621
   PubMed Web of Science ®Google Scholar
• ChenJHuangXFKatsifisAActivation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancerJ Cell Biochem201011151082108621053280
   PubMed Web of Science ®Google Scholar
• BardelliASienaSMolecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancerJ Clin Oncol20102871254126120100961
   PubMed Web of Science ®Google Scholar
• PintoCDi FabioFSienaSPhase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)Ann Oncol200718351051717164226
   PubMed Web of Science ®Google Scholar
• StellaGRojas LlimpeFLBaroneCKRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patientsJ Clin Oncol200927Suppl 15a15503
   Web of Science ®Google Scholar
• WuWKTseTTSungJJLiZJYuLChoCHExpression of ErbB receptors and their cognate ligands in gastric and colon cancer cell linesAnticancer Res200929122923419331154
   PubMed Web of Science ®Google Scholar
• TakiuchiHDoiTMuroKEverolimus in patients with previously treated metastatic gastric cancer: Final results of a multicenter phase II studyThe Proceedings of GI ASCO2010a52
   Google Scholar
• Van CutsemEYehKHBangYJPhase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1J Clin Oncol20124Suppl 30LBA3
   Web of Science ®Google Scholar
• SierraJRTsaoMSc-MET as a potential therapeutic target and biomarker in cancerTher Adv Med Oncol20113Suppl 1S21S3522128285
   PubMedGoogle Scholar
• ChristophDCSchulerMPolo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignanciesExpert Rev Anticancer Ther20111171115113021806334
   PubMed Web of Science ®Google Scholar
• IiMLiHAdachiYThe efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation statusClin Cancer Res201117155048505921642381
   PubMed Web of Science ®Google Scholar
• SankhalaKKMitaMMMitaACTakimotoCHHeat shock proteins: a potential anticancer targetCurr Drug Targets201112142001200821777196
   PubMed Web of Science ®Google Scholar
• MariniKDPayneBJWatkinsDNMartelottoLGMechanisms of Hedgehog signalling in cancerGrowth Factors201129622123421875383
   PubMed Web of Science ®Google Scholar